RAPT Therapeutics' stock plunges as FDA halts two clinical trials
By Eleanor Laise
Liver failure in trial participant prompts regulator's intervention
RAPT Therapeutics Inc. shares (RAPT) dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment due to liver failure in a trial participant.
The U.S. Food and Drug Administration has verbally notified RAPT that a clinical hold has been placed on two trials of zelnecirnon, one in atopic dermatitis and the other in asthma, the company said in a release Tuesday. RAPT said it expects to receive a formal clinical hold letter from the FDA, meaning the company must pause the trials.
The regulator's decision was based on "a serious adverse event" of liver failure in one patient participating in the atopic dermatitis trial, RAPT said. The cause of the liver failure is not known, but it "has been characterized as potentially related to zelnecirnon," the company said. There has been no evidence of liver toxicity in any other trial participants, the company said.
"RAPT is undertaking a thorough investigation of this case," the company said, which involved a patient with a complex medical history. Dosing of zelnecirnon and enrollment of new participants has been halted in both trials, the company said.
"Patient safety is our top priority and we will work with the FDA to resolve this as quickly as possible," Dr. Brian Wong, president and chief executive of RAPT, said in a statement.
Zelnecirnon is one of two lead assets for RAPT, which is also developing an experimental cancer treatment.
The experimental inflammation drug was seen as having "pipeline-in-a-product" potential, Goldman Sachs analysts wrote in a report late last year, meaning it could be effective in treating a range of conditions. But RAPT would need a partner to help develop zelnecirnon and move it to phase 3 trials, the analysts wrote.
RAPT shares are down 12.2% in the past 12 months, while the S&P 500 SPX has gained 22.7%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
02-20-24 0836ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year